NXT USA, a new organization developing unique nutraceutical solutions, has launched a joint health product. TamaFlex, unveiled in 2020, provides flexibility, comfort, and function in as little as 14 days. This outcome was determined in a 2019 study, and the results showed that the product reduced joint pain and stiffness. Furthermore, it improved physical function in 90 healthy subjects with joint discomfort caused by physical activity.
TamaFlex is unique because it targets the two pathways that cause joint inflammation; the COX-2 and 5-LOX enzyme pathways. While most joint health products address only one of the pathways, the product attends to both. TamaFlex also supports the integrity of connective tissues. “We are excited to bring TamaFlex to the market because we believe it fills an unmet need in the joint health market that products like glucosamine and chondroitin can’t address. The product addresses consumer demands by providing clean labels, vegan and non-GMO nutrients,” said Eric Anderson, Managing Director, NXT USA. “TamaFlex is also clinically validated in healthy participants, while most joint products rely on data from folks with health conditions,” he added.
The joint health product is a patent-pending combination of tamarind seed and turmeric rhizome extracts. TamaFlex is the first of its kind in the nutraceuticals market and incorporates the first tamarind seed extract available globally. Furthermore, it is backed by published safety data. While turmeric extracts are known for their anti-inflammatory benefits, NXT’s full-spectrum rhizome extracts indicate superior benefits for pain compared to 95% of curcuminoid products.
TamaFlex is the first patent-pending combination ingredient sustained by a double-blind study, with another nearing publication. Doses of 250 mg and 400 mg increased distance walked, reduced stair climb time, and pain scores measured by VAS, WOMAC pain, stiffness, and physical function scales compared to placebo. The health product also significantly improved knee flexion measured using a goniometer and physician global assessment score. It is available in a small daily dose that is fast-acting, protective, and lasting.
